Shorter Anti-HCV Regimen Effective in Patients With or Without Cirrhosis Shorter Anti-HCV Regimen Effective in Patients With or Without Cirrhosis

An eight-week regimen containing grazoprevir-ruzasvir-uprifosbuvir appears to be effective for treating hepatitis C virus (HCV) infection in patients with or without cirrhosis, according to findings from a pair of randomized phase 2 open-label trials.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Gastroenterology News Source Type: news